Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
Eleonora Sosa Cuevas, Stéphane Mouret, Guillaume Vayssière, Siham Kerboua, Pauline Girard, Jean-Paul Molens, Marc Manceau, Julie Charles, Philippe Saas, Caroline Aspord · 2024
Read Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment by Eleonora Sosa Cuevas, Stéphane Mouret, Guillaume Vayssière, Siham Kerboua, Pauline Girard, Jean-Paul Molens, Marc Manceau, Julie Charles, Philippe Saas, Caroline Aspord (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646980.txt.
Description
Eleonora Sosa Cuevas and co-authors map blood immune traits in melanoma patients on anti-PD1 therapy in a 2024 study. Checkpoint drugs bring big wins, yet many patients fail to respond or suffer immune side effects.
The team tracked blood immune cells before and during first-line treatment with deep flow methods. Responders began with more of certain dendritic cells, killer T cells, and memory gamma delta T cells. Treatment reshaped checkpoint marks, activation states, and killing receptor patterns across cell types. Dendritic cell function shifted, and T cell orientation changed deeply. The patterns link the starting immune landscape to outcome. Doctors may one day read blood to forecast who will gain.
Catalog record
| CREATOR | Eleonora Sosa Cuevas, Stéphane Mouret, Guillaume Vayssière, Siham Kerboua, Pauline Girard, Jean-Paul Molens, Marc Manceau, Julie Charles, Philippe Saas, Caroline Aspord |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |